Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bicycle Therapeutics plc - American Depositary Shares (NQ:BCYC)

6.680 -0.400 (-5.65%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bicycle Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Expert Ratings for Bicycle Therapeutics ↗
Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings: 
Via Benzinga
News headline image
Recap: Bicycle Therapeutics Q1 Earnings ↗
Bicycle Therapeutics (NASDAQ:BCYC) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
News headline image
B. Riley Securities Downgrades Rating to Neutral for Bicycle Therapeutics, Lowers Price Target To $33 ↗
B. Riley Securities downgraded its rating of Bicycle Therapeutics (NASDAQ:BCYC) to Neutral with a price target of $33.00, changing its price target from $62.00 to $33.00. Shares of Bicycle Therapeutics... 
Via Benzinga
News headline image
Where Bicycle Therapeutics Stands With Analysts ↗
Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2022 ↗
Upgrades 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers Hoth Therapeutics (NASDAQ:HOTH) stock rose 156.5% to $1.58 during Monday's pre-market session. The market value of their outstanding shares is at $37.8 million. 
Via Benzinga
News headline image
Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
News headline image
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More ↗
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion. 
Via Benzinga
News headline image
Why Bicycle Therapeutics Stock Is Soaring Today ↗
 
Via Benzinga
News headline image
Will Bicycle Therapeutics, With A 25% Gain Today, Take On Pfizer In Covid? ↗
Early-stage testing shows promise for this biotech company's Covid antiviral. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers Phio Pharma (NASDAQ:PHIO) shares increased by 46.7% to $1.33 during Friday's regular session. As of 13:31 EST, Phio Pharma's stock is trading at a volume... 
Via Benzinga
News headline image
Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
From Bicycle Therapeutics
Via Business Wire
News headline image
Bicycle Therapeutics Announces Updated Preclinical Data on SARS-CoV-2 Antivirals at the 2022 Microbiology Society Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics's Return On Capital Employed Overview ↗
Bicycle Therapeutics (NASDAQ:BCYC) brought in sales totaling $3.77 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 22.88%, resulting in a... 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Bicycle Therapeutics ↗
Analysts have provided the following ratings for Bicycle Therapeutics (NASDAQ:BCYC) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
Via Benzinga
News headline image
Bicycle Therapeutics: Q4 Earnings Insights ↗
Bicycle Therapeutics (NASDAQ:BCYC) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
News headline image
Bicycle Therapeutics to Participate at the 11th Annual SVB Leerink Global Healthcare Conference
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022 ↗
Upgrades According to Mizuho, the prior rating for Murphy Oil Corp (NYSE:MUR) was changed from Neutral to Buy. In the fourth quarter, Murphy Oil showed an EPS of $0.40,... 
Via Benzinga
News headline image
Bicycle Therapeutics Announces Continued Clinical Progress and Updates to Management Team
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Best Stocks Of 2021: Meme Stocks, Biotechs Highlight Broad Sector Strength ↗
The list features stocks from diverse sectors as the economy recovers from the pandemic. 
Via Investor's Business Daily
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021 ↗
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021 ↗
Upgrades According to Morgan Stanley, the prior rating for Definitive Healthcare Corp (NASDAQ: 
Via Benzinga
News headline image
7 A-Rated Biotechs to Buy for the Long Run ↗
The one thing the pandemic has shown us is biotechs are changing the way we treat diseases. These A-rated biotechs are great examples. 
Via InvestorPlace
News headline image
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics to Present Four Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist™ (Bicycle TICA™) Programs at the SITC 36th Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Looking Into Bicycle Therapeutics's Return On Capital Employed ↗
According to Benzinga Pro data, during Q3, Bicycle Therapeutics (NASDAQ:BCYC) posted sales of $4.33 million. Earnings were up 17.27%, but Bicycle Therapeutics still reported an... 
Via Benzinga
News headline image
Bicycle Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
News headline image
Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Tumor-targeted Immune Cell Agonist™ BT7480 in Patients with Advanced Solid Tumors Associated with Nectin-4 Expression
From Bicycle Therapeutics plc
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.